The Unprecedented Cannabis Reclassification Request

In a move that could have a profound impact on the cannabis industry, the U.S. Department of Health and Human Services has asked the Drug Enforcement Agency (DEA) to reconsider the regulation of cannabis during a review of its classification under the Controlled Substances Act.

This historic development marks the first time a federal entity has contemplated changing the classification of cannabis to a lower tier.

If this request is approved, it will carry significant implications for various aspects of the cannabis industry, including taxation, interstate commerce, and scientific research.

The Department of Health and Human Services’ request to revise the classification of cannabis represents a major boost for an industry that has faced restrictions imposed by federal regulations, despite the growth of legalization at the state level.

The proposal is to relocate cannabis to Schedule III controlled substances, along with compounds such as ketamine, anabolic steroids, and testosterone.

These substances are considered to have a moderate to low potential for physical or psychological dependence. Crucially, this recommendation would not eliminate the illegality of cannabis production, cultivation, and sale at the federal level, although cannabis is already legal for medical purposes in 39 states and for recreational purposes in 23 states.

The potential reclassification of cannabis as a Schedule III substance could alleviate various restrictions that have hindered the progress of the cannabis industry.

One of the main benefits would lie in the opportunity to take advantage of new tax benefits.

Currently, businesses operating with Schedule I substances cannot deduct expenses on their federal tax returns due to a provision of the Internal Revenue Code known as Section 280E. This situation has been a significant obstacle for many companies in the industry struggling to maintain profitability amid a slowdown in sales.

However, it is important to note that reclassification would not necessarily allow access to banking services for the industry, as Schedule III substances still pose a risk to banking institutions as long as federal laws remain unchanged. In Congress is a bill called the Safe and Equitable Banking for Enforcement (SAFE) Act that seeks to address this problem.

The request by the Department of Health and Human Services to reconsider the classification of cannabis represents an important step that could carry significant implications for the cannabis industry in the United States.